ADHD in Young Adults: Individualizing Treatment in 18-to 25-Year-Old Patients CME/CE

Author Information and Disclosures

Release Date: June 27, 2008; Valid for credit through June 27, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.5 nursing contact hours (0.75 contact hours are in the area of pharmacology)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Lilly
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss the impact of ADHD on quality of life and education in older adolescents
  2. Explore diagnostic considerations and management challenges encountered with ADHD in young adults
  3. Review the neurobiology of ADHD and discuss in relationship to various stimulant and nonstimulant treatment options
  4. Discuss the individualization of ADHD treatment in young adults based on symptoms and pharmacokinetic profiles, and identify approaches to choosing an alternative pharmacotherapy if/when initial choices are not tolerated or are ineffective
  5. Review appropriate management strategies for addressing comorbidities in young adults with ADHD, including the role of psychosocial therapies
  6. Describe best practices to improve adherence
Authors and Disclosures

Thomas E. Brown, PhD
Disclosure: Thomas E. Brown, PhD, has disclosed that he has received grants for clinical research from Eli Lilly. Dr. Brown has also disclosed that he has served as an advisor or consultant to Eli Lilly, Shire, and Novartis. Dr. Brown has also disclosed that he has received royalties for publications from the Psychological Corporation, American Psychiatric Press, and Yale University Press.


Priscilla Scherer, RN
Disclosure: Priscilla Scherer, RN, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.